Skip to main content
Premium Trial:

Request an Annual Quote

All Talk, But Where's the Action?

There is certainly no shortage of ambition in the Chinese pharmaceutical industry, says In the Pipeline's Derek Lowe. But does it have the resources and wherewithal to follow through? China already has a substantial contract research industry, and it seems clear, Lowe says, that a Chinese Merck or a Chinese Novartis eventually will exist. But the question is when will a Chinese startup, doing its own research with its own people in China develop its own international drug pipeline? Opinions differ, Lowe says, but a recent article in Chemical and Engineering News sheds some light on the issue. The article describes a new Chinese company that plans to launch its own breakthrough drugs within four years, manufacture the compounds, and sell them. But as of now, the company employs eight people and doesn't have an R&D lab or manufacturing facility. "Let me join those who dismiss business plans that are as ambitious as that one," Lowe says. "The way I understand the drug industry, if you're planning on launching a breakthrough drug within four years, you must have that drug in your hand right now, and it has to have had a lot of preclinical work done on it already."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.